Based on pre-clinical studies using aAVC-WT1,20 in this study, we performed the first-in-human study of aAVC-WT1-based cellular therapy in elderly patients with relapsed and refractory AML (RR-AML). This evidence concerns the gene WT1 and acute myeloid leukemia.